Abstract #4045
Effects of Trabectedine on tumour growth and metabolism in preclinical models of HER-2 overexpressing ovarian cancer
Egidio Iorio 1 , Fabio Ginnari Satriani 1 , Alessandro Ricci 1 , Emiliano Surrentino 1 , Marina Bagnoli 2 , Paola Alberti 2 , Franca Podo 1 , Delia Mezzanzanica 2 , and Rossella Canese 1
1
Cell Biology and Neurosciences Dept,
Istituto Superiore di Sanit, Rome, Italy,
2
Experimental
Oncology Dept, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy
Epithelial ovarian cancer (EOC) is a heterogeneous
disease with a poor prognosis. Evaluation of metabolic
effects of anticancer therapies would enhance the
capability of non invasive imaging approaches to monitor
molecular mechanisms underlying tumour responsiveness.
Here we explore the role of MRI/MRS in the detection of
the cytotoxic response of trabectedin (ET-743, a new
marine-derived antitumor agent, which has shown in vitro
and in vivo activity in ovarian cancer) in experimental
EOC models, showing previously unexplored trabectedine-induced
metabolic and morphofunctional changes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
